Halozyme Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1998-01-01
- Employees
- 373
- Market Cap
- $8B
- Website
- http://www.halozyme.com
- Introduction
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and a...
Safety Study of PEGPH20 Given to Patients With Advanced Solid Tumors
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2013-03-26
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 14
- Registration Number
- NCT00834704
- Locations
- 🇺🇸
Premiere Oncology, Santa Monica, California, United States
🇺🇸T Gen Clinical Research Services, Scottsdale, Arizona, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
Pharmacokinetic, Safety and Tolerability Study of SC Administered Bisphosphonate With rHuPH20 vs Bisphosphonate Alone
- Conditions
- Interventions
- First Posted Date
- 2008-12-15
- Last Posted Date
- 2018-08-15
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 31
- Registration Number
- NCT00807963
- Locations
- 🇺🇸
Healthcare Discoveries, LLC/ICON Development Solutions, San Antonio, Texas, United States
Dose-Ranging, Pharmacokinetic (PK), Glucodynamic (GD), Safety and Tolerability Study of Subcutaneously (SC) Administered Humulin R and Humalog With or Without rHuPH20
- Conditions
- Interventions
- First Posted Date
- 2008-12-08
- Last Posted Date
- 2018-08-15
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 42
- Registration Number
- NCT00803972
- Locations
- 🇺🇸
dgd Research, Inc., San Antonio, Texas, United States
Study of Immediate Post-Operative Intravesical Instillation of Chemophase® in Patients With Superficial Bladder Cancer
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2010-02-08
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 14
- Registration Number
- NCT00782587
- Locations
- 🇺🇸
Advanced Urology Medical Center, Anaheim, California, United States
🇺🇸BCG Oncology, PC, Phoenix, Arizona, United States
🇺🇸Medresearch, La Mesa, California, United States
Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2008-10-17
- Last Posted Date
- 2019-02-26
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 22
- Registration Number
- NCT00774800
- Locations
- 🇺🇸
Profil Institute for Clinical Research, Inc., Chula Vista, California, United States
Subcutaneous Rehydration Compared to Intravenous Rehydration
- First Posted Date
- 2008-10-16
- Last Posted Date
- 2018-11-07
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 148
- Registration Number
- NCT00773175
- Locations
- 🇺🇸
Children's Memorial Hospital, Chicago, Illinois, United States
🇺🇸Rainbow Children's and Babies Hospital, Cleveland, Ohio, United States
🇺🇸Children's Healthcare of Atlanta, Atlanta, Georgia, United States
Pharmacokinetic (PK), Pharmacodynamic (PD), and Safety Study of Subcutaneously Administered Humalog® With and Without Recombinant Human Hyaluronidase (rHuPH20)and Humulin-R® With and Without rHuPH20
- Conditions
- Interventions
- First Posted Date
- 2008-06-26
- Last Posted Date
- 2019-02-26
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 26
- Registration Number
- NCT00705536
- Locations
- 🇺🇸
Diabetes and Glandular Disease Research, Inc., San Antonio, Texas, United States
Study of Subcutaneous Hydration Enabled by Human Recombinant Hyaluronidase (Hylenex)
- First Posted Date
- 2008-04-11
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 15
- Registration Number
- NCT00656370
- Locations
- 🇺🇸
Jasper Clinic, Kalamazoo, Michigan, United States
INFUSE Morphine Study
- First Posted Date
- 2008-01-14
- Last Posted Date
- 2008-01-14
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 13
- Registration Number
- NCT00593281
- Locations
- 🇺🇸
UCSD Thornton Hospital, San Diego, California, United States
🇺🇸San Diego Hospice and Palliative Care, San Diego, California, United States
A Study of the Subcutaneous Injection of a Viscous Antibody Solution With Recombinant Human Hyaluronidase
- Conditions
- First Posted Date
- 2007-02-15
- Last Posted Date
- 2011-10-17
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 15
- Registration Number
- NCT00435604